Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Summary Panel Discussion: Discussing the Future of ADC Chemistry & Design to Herald a New Era of Bioconjugate Innovation

3:00 pm - Monday 12th October 2026

At the end of the seminar day, don’t miss this summary panel discussion to discuss, debate and challenge your speakers and ADC peers on the cutting-edge of ADC design, exploring the most promising areas of ADC innovation, benefits against traditional therapies, and hurdles to advance novel conjugates into and through the clinic.

Speakers:

Chet Metcalf

Vice President - Research & Development Chemistry

Regeneron Pharmaceuticals

Summary Panel Discussion: Discussing the Future of ADC Chemistry & Design to Herald a New Era of Bioconjugate Innovation

Summary Panel Discussion: Discussing the Future of ADC Chemistry & Design to Herald a New Era of Bioconjugate Innovation

Speakers:

Venue

Map

Contact

Join Our Team

About Us

Explore Our Products

Stay Connected

Search

Organized By